Since a 1 for 10 split to raise the PPS above $5 was preferred for the benefit of attracting additional news coverage, institution and other large investors, why would PPHM limit the R/S to a measly 1 for 5? Perhaps the explanation is PPHM is aware many shareholders are strongly opposed to any R/S but to protect against delisting, it was absolutely necessary to raise the PPS above $1 before the deadline. To keep all options open, PPHM must not be delisted. Why then would PPHM not be interested in the 1 for 10 split to attract additional news coverage, institution and other large investors? The reason could be PPHM has deals pending with one or more Big Pharma, awaiting the outcome of clinical trials, etc., and have reasons for structuring the R/S that are not now public knowledge. This may also explain retention of a large number of unissued shares that can be swapped or otherwise traded in a partnership, merger or acquisition. During personal discussion with an employee of a Big Pharma heavily involved in HIV research, the employee advised that many of his own company's experimental products failed during phase III trials and most Big Pharma, including his, are very skittish until favorable results have been documented. Don’t worry, be happy! PPHM management is doing a fantastic job of sailing this company to the promised land. Moby, get ready to deliver that JWB!
Market Data 
Markets 
AI
